Follow The Filings

IDXX Idexx Laboratories

Health Care, filed as IDEXX LABS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 3 managers in 2026 Q2, sold by 3

  • 8 Owners
  • #153
  • Max 3.9%
  • Master 0.11%
  • $1.9B
  • 1 new 2 add 3 reduce

In 2026 Q2, 1 manager opened a position, 2 added, and 3 trimmed.

Who owns this now

Largest portfolio weights among holders, up to 3.9% (Terry Smith, Fundsmith). Not free-float ownership.

  1. Terry Smith Reduce 3.9%
  2. Polen Capital Management Reduce 2.4%
  3. Ron Baron Add 1.6%
  4. Jensen Investment Management Add 1.4%
  5. Wallace Weitz 1.3%
  6. Farallon Capital Management New 0.02%

Who owns IDXX

Sorted by value, long equity only, as of 2026 Q2.

History
Ron Baron, Bamco Inc. (Baron Capital) 1.6% Add +21.0% 1,976,778 $1B History
Terry Smith, Fundsmith 3.9%, was 6.4% Reduce −30.4% 1,019,887 $537M History
Polen Capital Management 2.4%, was 2.7% Reduce −23.5% 532,384 $280M History
Jensen Investment Management 1.4%, was 0.04% Add +2861.0% 105,709 $56M History
Wallace Weitz, Weitz Investment Management 1.3% Hold 35,300 $19M History
Farallon Capital Management 0.02% New 0.02% 9,000 $4.7M History
Mairs & Power 0.01% Hold 2,080 $1.1M History
Bill Nygren / Oakmark, Harris Associates L P <0.01% Reduce −5.6% 455 $240K History

8 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by IDXX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All IDXX insider trades
  • None no insider bought on the open market
  • $37.7M sold by 6 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Lawrence D Kingsley Director
    Sale
    $1.2M 2,203 shares at $532.08 19% of stake
    Traded Sep 4 Filed Sep 9
    ↗
  2. Nimrata Hunt Executive Vice President
    Sale
    $1.1M 1,758 shares at $634.57 8.8% of stake
    Traded Mar 3 Filed Mar 5
    ↗
  3. Jonathan Jay Mazelsky CEO
    Sale
    $15.3M 23,326 shares at $657.55 22% of stake
    Traded Feb 26 Filed Mar 2
    ↗
  4. Nimrata Hunt Executive Vice President
    Sale
    $1.8M 2,693 shares at $661.54 12% of stake
    Traded Feb 26 Filed Feb 27
    ↗
  5. Michael G Erickson Executive Vice President
    Sale
    $3.4M 5,371 shares at $627.38 30% of stake
    Traded Feb 17 Filed Feb 19
    ↗
  6. Sophie V. Vandebroek Director
    Sale
    $920K 1,464 shares at $628.62 69% of stake
    Traded Feb 17 Filed Feb 19
    ↗
  7. George Fennell Executive Vice President
    Sale
    $7.3M 11,345 shares at $646.72 54% of stake
    Traded Feb 10 Filed Feb 11
    ↗
  8. Nimrata Hunt Executive Vice President
    Sale
    $6.6M 9,425 shares at $703.34 31% of stake
    Traded Nov 7, 2025 Filed Nov 10, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 67 option exercises, 12 share withholdings for taxes, and 4 stock grants.

Congress

5 members of Congress traded IDXX in the last three years: 11 buys and 10 sales. 4 members listed it in 2025 annual reports.

All Congress trades
  1. April McClain Delaney D-MD-6Child Sell $1K–$15K Jan 13 filed Feb 2
  2. April McClain Delaney D-MD-6Child Partial sale $1K–$15K Dec 2, 2025 filed Jan 5
  3. April McClain Delaney D-MD-6Child Partial sale $1K–$15K Oct 29, 2025 filed Nov 4, 2025
  4. April McClain Delaney D-MD-6Child Partial sale $1K–$15K Oct 16, 2025 filed Nov 4, 2025
  5. Byron Donalds R-FL-19Spouse Buy $1K–$15K Sep 4, 2025 filed Oct 7, 2025
  6. Byron Donalds R-FL-19 Buy $1K–$15K Sep 4, 2025 filed Oct 7, 2025

SEC filings

Recent issuer filings from EDGAR, 11 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.03,5.07,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 5.02,9.01 Filing Doc
10-K Filing Doc

Source: SEC EDGAR submissions, updated 12 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $3.66B $3.9B $4.3B
Gross profit $2.19B $2.38B $2.66B
Gross margin * 59.8% 61.0% 61.8%
Net income $0.845B $0.888B $1.06B
Net margin * 23.1% 22.8% 24.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.5B $1.4B $1.41B
Total non-current assets $1.76B $1.89B $1.94B
Total assets $3.26B $3.29B $3.35B
Total current liabilities $0.952B $1.07B $1.15B
Total non-current liabilities $823.85M $630.21M $596.56M
Total equity $1.48B $1.6B $1.61B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $0.907B $0.929B $1.18B
Cash from investing -$125.25M -$207.06M -$136.24M
Cash from financing -$0.442B -$0.878B -$1.16B
Net change in cash $341.39M -$165.67M -$108.2M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.